This is a single arm explorative phase II clinical trial in 90 subjects with advanced stage
melanoma harbouring a BRAFV600 mutation. PET imaging and molecular diagnostics are combined
in order to monitor response to treatment with vemurafenib plus cobimetinib, examine
development of resistance and correlate changes in metabolic/proliferative activity with
extend of target inhibition.